<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450450</url>
  </required_header>
  <id_info>
    <org_study_id>ASCT0631</org_study_id>
    <secondary_id>NCI-2009-01069</secondary_id>
    <secondary_id>COG-ASCT0631</secondary_id>
    <secondary_id>COG-PBMTC-STC051</secondary_id>
    <secondary_id>CDR0000532926</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00450450</nct_id>
  </id_info>
  <brief_title>Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases</brief_title>
  <official_title>A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying donor bone marrow transplant with or without
      G-CSF to compare how well they work in treating young patients with hematologic cancer or
      other diseases. Giving chemotherapy and total-body irradiation before a donor bone marrow
      transplant helps stop the growth of cancer or abnormal cells. It also helps stop the
      patient's immune system from rejecting the donor's stem cells. When the healthy stem cells
      from a donor are infused into the patient they may help the patient's bone marrow make stem
      cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells
      from a donor can make an immune response against the body's normal cells. Giving methotrexate
      and tacrolimus or cyclosporine before and after transplant may stop this from happening. It
      is not yet known whether donor bone marrow transplant is more effective with or without G-CSF
      in treating hematologic cancer or other diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. Compare improvement in event-free survival of patients with hematologic cancer or other
      diseases undergoing filgrastim (G-CSF)-stimulated bone marrow transplantation (BMT) vs
      conventional BMT.

      SECONDARY OBJECTIVES:

      I. Compare the incidence and time to engraftment in patients treated with these regimens.

      II. Compare rates of acute and chronic graft-vs-host disease (GVHD) in patients treated with
      these regimens.

      III. Correlate incidence of acute and chronic GVHD with absolute T-cell numbers, Th1 vs Th2
      profile of T cells, dendritic cell populations, and T-regulatory cell content.

      IV. Assess the impact of G-CSF-stimulated BMT as a stem cell source on hospital stay and
      treatment-related mortality at day 100 in patients treated with this regimen.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to risk
      (high vs intermediate vs standard).

      CONDITIONING REGIMEN: Co-enrolled on COG-ASCT0431 or COG-AAML0531; Patients receive a
      conditioning regimen as defined on that treatment study.

      ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): Patients undergo total-body irradiation (TBI) twice daily
      on days -8 to -6. Patients receive thiotepa IV on days -5 and -4 and high-dose
      cyclophosphamide IV over 1 hour on days -3 and -2. Some patients with CNS leukemia or very
      high-risk ALL in first complete remission receive cranial radiotherapy.

      ACUTE MYELOID LEUKEMIA, JUVENILE MYELOMONOCYTIC, CHRONIC MYELOGENOUS LEUKEMIA, OR
      MYELODYSPLASTIC SYNDROMES: (myeloid malignancies) Patients receive busulfan IV over 2 hours
      every 6 hours on days -9 to -6 and high-dose cyclophosphamide IV over 1 hour on days -5 to
      -2.

      GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Co-enrolled on COG-ASCT0431 or COG-AAML0531:
      Patients undergo GVHD prophylaxis as defined on that treatment study.

      ALL: Patients receive tacrolimus IV or orally beginning on day -2 and continuing until day
      42, followed by a taper until day 98. Patients also receive methotrexate IV on days 1, 3, and
      6.

      MYELOID MALIGNANCIES: Patients receive cyclosporine IV continuously or orally beginning on
      day -1 and continuing until day 42 or day 50, followed by a taper for 8-16 weeks. Patients
      also receive methotrexate IV on days 1, 3, 6, and 11.

      ALLOGENEIC BONE MARROW TRANSPLANTATION (BMT): Patients are randomized to 1 of 2
      transplantation arms.

      ARM I: Patients undergo filgrastim (G-CSF) -stimulated allogeneic BMT on day 0.

      ARM II: Patients undergo conventional allogeneic BMT on day 0.

      After completion of study treatment, patients are followed at 1 year and then annually for
      5-10 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Two-year Event-free Survival (EFS)</measure>
    <time_frame>at 2 years</time_frame>
    <description>EFS is defined as relapse or treatment-related mortality (TRM). relapse is defined by either morphological or cytogenetic evidence of ALL consistent with pre-transplant features.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated Graft Failure Rate</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Primary graft failure is defined as the failure to achieve an absolute neutrophil count of more than 5000 per cubic millimeter for at least three consecutive days by Day +42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Incidence of Grade III-IV Acute Graft-versus-host Disease (aGVHD)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Stage III-IV aGVHD is defined as: Stage 0-3 skin, with Stage 2-3 liver, or Stage 2-3 GI; OR Stage 4 skin, liver or GI involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated 100-day Transplant Related Mortality (TRM) Percentage</measure>
    <time_frame>100 days</time_frame>
    <description>Death in a patient after transplant due to protocol treatment is defined as an TRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Percentage of Chronic Graft-versus-host Disease (cGVHD)</measure>
    <time_frame>18 months post-transplant</time_frame>
    <description>cGVHD definition is based on BMT CTN MOP SEPT. 2005; outlined in Protocol Appendix III.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Median Time to Neutrophil Engraftment</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Median Time from transplant to neutrophil engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Median Length of Initial Hospitalization</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Estimated and compared between randomization arms using the Wilcoxon rank-sum test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune Reconstitution</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summarized graphically. Generalized estimating equation will be used to model the levels as a function of time and randomization assignment and to test the impact of G-CSF stimulation on immune reconstruction.</description>
  </other_outcome>
  <other_outcome>
    <measure>Infused Nucleated and CD34+ Cell Doses</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Compared using the Wilcoxon rank-sum test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo filgrastim (G-CSF)-stimulated allogeneic bone marrow transplantation on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo conventional allogeneic bone marrow transplantation on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>Patients undergo allogeneic BMT</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>bone marrow therapy, allogeneic</other_name>
    <other_name>bone marrow therapy, allogenic</other_name>
    <other_name>transplantation, allogeneic bone marrow</other_name>
    <other_name>transplantation, allogenic bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Granulocyte Colony-Stimulating Factor</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>NSC #614629</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hematologic cancer or other disease, including any of the following:

               -  Chronic myelogenous leukemia in first or second chronic phase

               -  Acute lymphoblastic leukemia (ALL), meeting any of the following criteria:

                    -  Relapsed ALL enrolled on a Children's Oncology Group (COG) relapse clinical
                       trial OR received ≥ 1 round of reinduction therapy (4-6 weeks) and 1 round
                       of intensive consolidation chemotherapy (3-6 weeks)

                    -  ALL in second complete remission (CR)* after a bone marrow, extramedullary,
                       or combined bone marrow and extramedullary relapse

                    -  Very high-risk ALL in first CR, defined as any of the following:

                         -  Philadelphia chromosome-positive ALL

                         -  Hypodiploidy (&lt; 44 chromosomes)

                         -  Mixed lineage leukemia rearrangement

                         -  Induction failure

               -  Acute myeloid leukemia in first or second CR

                    -  Induction therapy must be completed

               -  Juvenile myelomonocytic leukemia

               -  Myelodysplastic syndromes

          -  No clinically evident CNS or extramedullary disease

          -  No blasts seen on cerebrospinal fluid cytospin

          -  Post-relapse reinduction therapy must be completed

          -  Not planning to receive reduced-intensity conditioning regimen

          -  Not planning to receive a graft that has undergone T-cell depletion

          -  No Down syndrome

          -  Matched sibling donor must be available and must be enrolled on ASCT0631D companion
             study

          -  Karnofsky performance status (PS) 60-100% (patients &gt; 16 years of age) OR Lansky PS
             60-100% (patients ≤ 16 years of age)

          -  AST or ALT &lt; 5 times upper limit of normal for age

          -  Bilirubin &lt; 2.5 mg/dL (unless due to Gilbert's syndrome)

          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum
             creatinine base on age and/or gender as follows:

               -  0.4 mg/dL (1 month to &lt; 6 months of age)

               -  0.5 mg/dL (6 months to &lt; 1 year of age)

               -  0.6 mg/dL (1 to 2 years of age)

               -  0.8 mg/dL (2 to &lt; 6 years of age)

               -  1.0 mg/dL (6 to &lt; 10 years of age)

               -  1.2 mg/dL (10 to &lt; 13 years of age)

               -  1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to &lt; 16 years of age)

               -  1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)

          -  Shortening fraction ≥ 27% by echocardiogram OR LVEF ≥ 50% by radionuclide angiogram

          -  FEV_1, FVC, and DLCO ≥ 60% OR meets the following criteria (for patients unable to
             cooperate for pulmonary function tests):

               -  No evidence of dyspnea at rest

               -  No exercise intolerance

               -  No requirement for supplemental oxygen therapy

          -  Not pregnant or nursing

          -  No known HIV

          -  No known uncontrolled fungal, bacterial, or viral infections

               -  Patients acquiring fungal disease during induction therapy may proceed if they
                  have a significant response to antifungal therapy with no or minimal evidence of
                  disease remaining by CT scan

          -  No prior allogeneic or autologous stem cell transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan A. Grupp, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <results_first_submitted>November 10, 2016</results_first_submitted>
  <results_first_submitted_qc>March 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2017</results_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control BM Arm</title>
          <description>Conventional bone marrow transplant (BM)</description>
        </group>
        <group group_id="P2">
          <title>Experimental G-BM Arm</title>
          <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing Data</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Group 2 enrollment total is 14, patient 774353 enrolled on study, but was not randomized and didn’t contribute any data. Group 2 AE total is 13.</population>
      <group_list>
        <group group_id="B1">
          <title>Control BM Arm</title>
          <description>Conventional bone marrow transplant (BM)</description>
        </group>
        <group group_id="B2">
          <title>Experimental G-BM Arm</title>
          <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Whole year</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="B2" value="11" lower_limit="3" upper_limit="20"/>
                    <measurement group_id="B3" value="12" lower_limit="0" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimated Two-year Event-free Survival (EFS)</title>
        <description>EFS is defined as relapse or treatment-related mortality (TRM). relapse is defined by either morphological or cytogenetic evidence of ALL consistent with pre-transplant features.</description>
        <time_frame>at 2 years</time_frame>
        <population>Early terminated study. One patient is inevaluable for EFS on experimental arm and is excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control BM Arm</title>
            <description>Conventional bone marrow transplant (BM)</description>
          </group>
          <group group_id="O2">
            <title>Experimental G-BM Arm</title>
            <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Two-year Event-free Survival (EFS)</title>
          <description>EFS is defined as relapse or treatment-related mortality (TRM). relapse is defined by either morphological or cytogenetic evidence of ALL consistent with pre-transplant features.</description>
          <population>Early terminated study. One patient is inevaluable for EFS on experimental arm and is excluded from analysis.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="32" upper_limit="86"/>
                    <measurement group_id="O2" value="83" lower_limit="47" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Graft Failure Rate</title>
        <description>Primary graft failure is defined as the failure to achieve an absolute neutrophil count of more than 5000 per cubic millimeter for at least three consecutive days by Day +42.</description>
        <time_frame>Up to 10 years</time_frame>
        <population>One patient is inevaluable for EFS on experimental arm and is excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control BM Arm</title>
            <description>Conventional bone marrow transplant (BM)</description>
          </group>
          <group group_id="O2">
            <title>Experimental G-BM Arm</title>
            <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Graft Failure Rate</title>
          <description>Primary graft failure is defined as the failure to achieve an absolute neutrophil count of more than 5000 per cubic millimeter for at least three consecutive days by Day +42.</description>
          <population>One patient is inevaluable for EFS on experimental arm and is excluded from analysis.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Incidence of Grade III-IV Acute Graft-versus-host Disease (aGVHD)</title>
        <description>Stage III-IV aGVHD is defined as: Stage 0-3 skin, with Stage 2-3 liver, or Stage 2-3 GI; OR Stage 4 skin, liver or GI involvement.</description>
        <time_frame>Up to 3 months</time_frame>
        <population>One patient is inevaluable and is excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control BM Arm</title>
            <description>Conventional bone marrow transplant (BM)</description>
          </group>
          <group group_id="O2">
            <title>Experimental G-BM Arm</title>
            <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Incidence of Grade III-IV Acute Graft-versus-host Disease (aGVHD)</title>
          <description>Stage III-IV aGVHD is defined as: Stage 0-3 skin, with Stage 2-3 liver, or Stage 2-3 GI; OR Stage 4 skin, liver or GI involvement.</description>
          <population>One patient is inevaluable and is excluded from analysis.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69"/>
                    <measurement group_id="O2" value="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated 100-day Transplant Related Mortality (TRM) Percentage</title>
        <description>Death in a patient after transplant due to protocol treatment is defined as an TRM.</description>
        <time_frame>100 days</time_frame>
        <population>One patient is inevaluable and is excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control BM Arm</title>
            <description>Conventional bone marrow transplant (BM)</description>
          </group>
          <group group_id="O2">
            <title>Experimental G-BM Arm</title>
            <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated 100-day Transplant Related Mortality (TRM) Percentage</title>
          <description>Death in a patient after transplant due to protocol treatment is defined as an TRM.</description>
          <population>One patient is inevaluable and is excluded from analysis.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Percentage of Chronic Graft-versus-host Disease (cGVHD)</title>
        <description>cGVHD definition is based on BMT CTN MOP SEPT. 2005; outlined in Protocol Appendix III.</description>
        <time_frame>18 months post-transplant</time_frame>
        <population>Included only patients survived beyond 100 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Control BM Arm</title>
            <description>Conventional bone marrow transplant (BM)</description>
          </group>
          <group group_id="O2">
            <title>Experimental G-BM Arm</title>
            <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Percentage of Chronic Graft-versus-host Disease (cGVHD)</title>
          <description>cGVHD definition is based on BMT CTN MOP SEPT. 2005; outlined in Protocol Appendix III.</description>
          <population>Included only patients survived beyond 100 days.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Median Time to Neutrophil Engraftment</title>
        <description>Median Time from transplant to neutrophil engraftment</description>
        <time_frame>Up to 10 years</time_frame>
        <population>One patient was inevaluable and excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control BM Arm</title>
            <description>Conventional bone marrow transplant (BM)</description>
          </group>
          <group group_id="O2">
            <title>Experimental G-BM Arm</title>
            <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Median Time to Neutrophil Engraftment</title>
          <description>Median Time from transplant to neutrophil engraftment</description>
          <population>One patient was inevaluable and excluded from the analysis.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="20" upper_limit="25"/>
                    <measurement group_id="O2" value="20" lower_limit="16" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Median Length of Initial Hospitalization</title>
        <description>Estimated and compared between randomization arms using the Wilcoxon rank-sum test.</description>
        <time_frame>Up to 10 years</time_frame>
        <population>Data regarding length of Initial Hospitalization are not collected for this study according to Study Chair.</population>
        <group_list>
          <group group_id="O1">
            <title>Control BM Arm</title>
            <description>Conventional bone marrow transplant (BM)</description>
          </group>
          <group group_id="O2">
            <title>Experimental G-BM Arm</title>
            <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Median Length of Initial Hospitalization</title>
          <description>Estimated and compared between randomization arms using the Wilcoxon rank-sum test.</description>
          <population>Data regarding length of Initial Hospitalization are not collected for this study according to Study Chair.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immune Reconstitution</title>
        <description>Summarized graphically. Generalized estimating equation will be used to model the levels as a function of time and randomization assignment and to test the impact of G-CSF stimulation on immune reconstruction.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Data are not collected for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Control BM Arm</title>
            <description>Conventional bone marrow transplant (BM)</description>
          </group>
          <group group_id="O2">
            <title>Experimental G-BM Arm</title>
            <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution</title>
          <description>Summarized graphically. Generalized estimating equation will be used to model the levels as a function of time and randomization assignment and to test the impact of G-CSF stimulation on immune reconstruction.</description>
          <population>Data are not collected for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Infused Nucleated and CD34+ Cell Doses</title>
        <description>Compared using the Wilcoxon rank-sum test.</description>
        <time_frame>Up to 10 years</time_frame>
        <population>Data are not collected for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Control BM Arm</title>
            <description>Conventional bone marrow transplant (BM)</description>
          </group>
          <group group_id="O2">
            <title>Experimental G-BM Arm</title>
            <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
          </group>
        </group_list>
        <measure>
          <title>Infused Nucleated and CD34+ Cell Doses</title>
          <description>Compared using the Wilcoxon rank-sum test.</description>
          <population>Data are not collected for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Group 2 enrollment total is 14, patient 774353 enrolled on study, but was not randomized and didn’t contribute any data. Group 2 AE total is 13.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control BM Arm</title>
          <description>Conventional bone marrow transplant (BM)</description>
        </group>
        <group group_id="E2">
          <title>Experimental G-BM Arm</title>
          <description>G-CSF (filgrastim) stimulated bone marrow (G-BM)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rectal mucositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain prior Sponsor approval.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>ASCT0631 is closed to further patient entry as of 11/25/2011 due to poor accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

